ea0016oc1.4 | Neuroendocrinology and pituitary | ECE2008
Farrall Andrew J
, Glusman Joan E
, Ruffin Matthieu
, Petersenn Stephan
Introduction: In a recent 16-week Phase II study in patients with de novo, persistent or recurrent acromegaly, pasireotide effectively controlled GH and/or IGF-I levels in 56% of patients, and reduced tumor volume by >20% in 39% of patients. We present preliminary 6-month results from the ongoing extension phase of this study.Methods: This extension study enrolled patients who achieved biochemical control (GH ≤2.5 μg/l and normalize...